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Purpose: Postmenopausal osteoporosis causes bone fracture as well as pain, physical, 
psychological and socially adverse effects, which affects a patient’s quality of life (QOL). 
The effect of alendronate on QOL was investigated compared with that of alfacalcidol in post-
menopausal osteoporotic women.
Patients and methods: A total of 44 postmenopausal osteoporotic women (mean age 
69.8 years) with back or joint pain, although capable of walking, were randomly assigned to 
two groups; group A (n = 25) received 5 mg/day of alendronate, and group B (n = 19) received 
0.5 µg/day of alfacalcidol, for the first 4 months. For the following 2 months, the group A 
received 0.5 µg/day of alfacalcidol and the group B received 5 mg/day of alendronate in a 
crossover design. The patient’s QOL was evaluated by score of Japanese Osteoporosis Quality 
of Life Questionnaire (JOQOL), and pain intensity using a visual analog scale (VAS). Bone 
metabolism was measured by bone mineral density (BMD) and a biomarker for bone resorption, 
urinary crosslinked N-terminal telopeptide of type I collagen (NTX).
Results: With 4-month treatment, alendronate, but not alfacalcidol, improved pain-related QOL, 
reduced joint pain by VAS, and increased bone mineral density. Both treatments significantly 
reduced bone resorption, the inhibition was significantly higher with alendronate (−56.5%) 
compared with alfacalcidol (−18.1%). After crossover, the patients in group A received alfa-
calcidol and had a reduced total and daily living activity-related QOL scores, and increased 
upper back pain by VAS. The group B received alendronate had significantly reduced bone 
resorption after the 2 months.
Conclusion: Alendronate improves the QOL of Japanese postmenopausal women with osteo-
porosis by reducing pain intensity as well as increasing bone mineral density.
Keywords: osteoporosis, bisphosphonates, quality of life, pain, vitamin D
Introduction
Patients affected by age-related diseases have been increasing in recent years as 
the numbers of our elderly population has been increasing. This is especially so for 
the condition of postmenopausal osteoporosis which frequently causes impaired the 
physical, psychological and social life of the patients due to bone fractures or pain; in 
addition it also an added health care burden to society.1–6 Thus, it is important to find 
osteoporosis treatment which can maintain or improve a patient’s quality of life (QOL) 
as well as prevent bone fracture. Bisphosphonates have been developed as osteoporosis 
drugs which improve pain in lower back as well as QOL in the patients suffering this 
condition to increase bone mass by inhibiting bone resorption and by preventing bone 
fracture.7–9 This is especially so for alendronate which reduces pain and improves QOL 
more effectively, than compared to calcium monotherapy, in post menopausal women Clinical Interventions in Aging 2010:5 124
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in osteoporosis. However, the effect of bisphosphonates 
on improving QOL in osteoporotic patients has not been 
reported in a randomized controlled study in Japan to date. 
In the present study, we examined the effect of alendronate 
on QOL and pain in postmenopausal Japanese women with 
osteoporosis using a randomized comparative crossover 
design. Alfacalcidol was used as a comparative drug, as it 
has been reported to reduce the low back pain in an earlier 
double-blind study in Japan.10
Materials and methods
Study design
This is a randomized comparative study conducted in 
post menopausal women with osteoporosis who had been 
recruited in the outpatient clinics of 10 medical institutions 
within the Fukuoka prefecture, Japan, who were suffering 
pain in the lower back, the upper back or joints, although 
they were capable of walking. Osteoporosis was defined 
by criteria given by the Japanese Society for Bone and 
Mineral Research as; less than 70% of bone mineral density 
of the young adult mean (T-score  −2.5). The patients 
were excluded if they had osteomalacia, renal dysfunction 
(serum creatinine 1.5 mg/dL), malignant tumor, insulin 
therapy and bisphosphonates therapy within 6 months. 
The study prohibited the use of drugs which might affect 
bone metabolism such as calcitonin, ipriflavone, vitamin 
K, and estrogen products. Patients who had been taking 
anti-inflammatory drugs, including patches and cream did 
not change either the drug and/or the dosage postregistration. 
The patients who initially required long-term treatment with 
anti-inflammatory drugs were excluded. At the baseline, 
patients were interviewed for family history of osteoporosis, 
pain and QOL assessment. X-rays of the lumbar vertebrae 
were taken to examine the presence of bone fracture.
A total of 44 registered patients were centrally random-
ized into two groups; group A (n = 25) receiving 5 mg/day 
of alendronate for the first 4 months and 0.5 µg/day of alfa-
calcidol for the following 2 months, and group B (n = 19) 
receiving 0.5 µg/day of alfacalcidol for the first 4 months and 
5 mg/day of alendronate for the following 2 months as shown 
in Figure 1. The data of 10 patients were excluded from the 
analysis as; 4 patients did not have QOL data and 3 patients 
Randomly assigned (n = 44)
Alendronate (n = 18)
(4 months)
Alfacalcidol (n = 16)
(4 months)
Group A: Alfacalcidol
(n = 13)
(2 months)
Group B: Alendronate
(n = 10) 
(2 months)
Crossover
Group A: Alendronate (n = 25)
Patients without JOQOL
data at  month 4 (n = 4)
Lost in follow-up (n = 3)
Lost in follow-up (n = 3)
Group B: Alfacalcidol (n = 19)
Figure 1 Enrollment and outcomes.
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were lost in the follow-up of group A, and 3 patients were 
lost in the follow-up of group B. The data of 34 patients, 
18 patients in the group A and 16 patients in the group B, 
were analyzed in the present study for the first 4 months. 
A total of 13 patients in the group A and 10 patients in the 
group B who completed the additional 2 months study after 
the crossover, were included for analysis.
The differences in QOL and pain were evaluated between 
alendronate treatment and alfacalcidol treatment with the 
following methods.
For the primary endpoint, a change in patient QOL, the 
QOL was assessed by Japanese Osteoporosis Quality of Life 
Questionnaire (JOQOL) consisting with 38 questions in six 
categories (pain, daily living activity, recreational and social 
activities, general health conditions, posture and figure, falls 
and the psychological effects pertaining to the condition) 
at the baseline, at 4 and 6 months. Patient response to each 
question was scored using a points scale from 0 to 4; giving 
4 points at maximum.11 The six categories included areas 
related to: “pain” (5 questions with total of 20 points); “daily 
living activity” (16 questions with 64 points); “recreational 
and social activities” (5 questions with 20 points); “general 
health condition” (3 questions with 12 points); “posture and 
figure” (4 questions with 16 points); and “fall and its psy-
chological effects” (5 questions with 20 points); with total of 
152 points. The higher score indicated a higher QOL.
Pain was also assessed by visual analog scale (VAS) of 10 
points at the baseline, 4 and 6 months for pain in the upper 
back, the lower back and the joints. Bone mineral density of 
lumbar vertebrae was measured by dual X-ray absorptiom-
etry (DXA) at the baseline and 4 months. It was measured 
at Kyushu University and Fukuoka Teishin Hospital with the 
same measuring devices, QDR_4500 (Hologic, Tokyo, Japan). 
Bone resorption was measured by the marker, urinary cross-
linked N-terminal telopeptide of type I collagen (NTX) at the 
baseline then at 4 and 6 months. All biochemical markers were 
measured centrally at SRL (Special Reference Laboratories, 
Tokyo, Japan). The observation period after the crossover was 
limited to 2 months for ethical reasons, since exacerbation of 
the clinical condition was previously observed in the patients 
who had switched from alendronate to alfacalcidol.
Statistical analysis
We focused on improvements on the pain score in estimat-
ing the required sample size in each group. Because of a 
lack of information about expected improvement in the pain 
score and its variation, we calculated the sample sizes under 
different conditions with a two-sided significance level of 
0.05 and 80% power. We also assumed that the standard 
deviation (SD) for improvements was 5 points. When the 
improvements in the pain score were 3, 4 or 5 points by 
the alendronate treatment, the required sample sizes were 
estimated to be 22, 13 and 8, respectively.
The values were expressed as mean ± SD. The differences 
in baseline characteristics among groups were evaluated by 
a Chi-square test, Student’s T-test, or ANOVA, followed by 
Tukey test. The differences in scores between the two groups 
were evaluated by Mann–Whitney U test. The differences 
in percent change of bone marrow density (BMD) or NTX 
within the same group was evaluated between the baseline 
and that of 4 months or 6 months with ANOVA followed by 
Tukey test. The difference with P  0.05 was considered to 
be significant.
All statistical calculations were performed with SPSS 
(SPSS Inc., Chicago, IL, USA), and/or Statistica (StatSoft, 
Tulsa, OK, USA) computer software.
Results
The baseline characteristics of 34 patients who completed 
the first 4 months of treatment were compared between the 
two groups as shown in Table 1. No significant differences 
in age, BMD, or the incidence of lumbar vertebral fracture 
were observed between the two groups. Pain intensity using 
the VAS in joints (4.2 ± 2.0 versus 2.7 ± 1.8) and QOL 
impairment in “recreational and social activities” were 
significantly higher in the group A (alendronate) and the 
number of patients with a family history of osteoporosis were 
significantly higher in the group B (alfacalcidol).
During the first 4-month treatment, the patient QOL 
according to the total QOL score indicated a tendency to 
improve with both alendronate and alfacalcidol. Although 
alfacalcidol significantly improved the total QOL score, the 
average changes were similar between the two treatments 
(Figure 2). Furthermore, the pain related QOL was sig-
nificantly improved by alendronate, but not by alfacalcidol, 
according to the QOL scores of six categories.
Based on VAS, the pain intensity of joints was signifi-
cantly reduced by alendronate, while the intensity did not sig-
nificantly change in any regions by alfacalcidol (Figure 3).
Although a tendency of increased BMD of the lumbar 
vertebrae was observed in both groups, only the treatment 
with alendronate significantly increased the BMD from the 
baseline with the 4-month alendronate treatment (0.637 ± 
0.149 versus 0.659 ± 0.159, P  0.001) (Figure 4a). Further-
more, both alendronate and alfacalcidol reduced bone resorp-
tion as measured by urinary NTX. Alendronate significantly Clinical Interventions in Aging 2010:5 126
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Table 1 Baseline patient characteristics
Characteristic Group A (n = 18) alendronate Group B (n = 16) alfacalcidol P value
Age (year) 66.7 ± 9.1 72.7 ± 8.1 ns
BMD Lumbar vertebrae (g/cm²) 0.637 ± 0.149 0.628 ± 0.137 ns
Urinary NTX (nM BCE/nM Cr) 56.4 ± 25.4 53.0 ± 23.4 ns
Vertebral fractures at baseline (yes/no) 4/13 4/12 ns
Family history of osteoporosis (yes/no) 3/15 9/7 0.05
VAS (lower back) 4.8 ± 2.4 3.3 ± 1.7 ns
VAS (upper back) 3.1 ± 2.1 3.1 ± 2.3 ns
VAS (joints) 4.2 ± 2.0 2.7 ± 1.8 0.05
JOQOL
Pain (20 points) 12.3 ± 4.3 13.5 ± 4.0 ns
Activity of daily living (64 points) 58.1 ± 8.0 56.8 ± 10.4 ns
Recreational and social activities (20 points) 11.6 ± 4.9 8.3 ± 4.8 0.05
General health (12 points) 7.5 ± 3.3 7.1 ± 3.2 ns
Posture and figure (16 points) 10.0 ± 4.4 9.6 ± 2.3 ns
Falls and the psychological effects (20 points) 12.8 ± 3.8 11.8 ± 3.6 ns
Total QOL score (152 points) 73.3 ± 12.3 70.4 ± 10.0
ns
ns
Abbreviations: NS, not significant; QOL, quality of life;   VAS, visual analog scale; JOQOL, Japanese Osteoporosis Quality of Life Questionnaire; BMD, bone mineral density; 
NTX, urinary crosslinked N-terminal telopeptide of type I collagen, BCE, bone collagen-equivalent; Cr, creatinine.
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Figure 3 Comparison of pain intensity reduction between alendronate and alfacalcidol treatments during the first 4 months according to visual analog scale of 10 points. Pain 
was assessed in lower back, upper back and joints.
Note: *P  0.05 vs baseline.
suppressed the bone resorption more than alfacalcidol 
(−57% versus −18%, P  0.001) as shown in Figure 4b.
Crossover
After the first 4-month treatment, the patients were followed 
for 2 months after the crossover to the other drug. A total 
of 13 patients in the group A received alfacalcidol and 
10 patients in the group B received alendronate. The two 
groups had similar patient characteristics (except age) at the 
end of the first 4-month treatment. Mean age was significantly 
lower in the group A than in the group B (age 65.9 ± 8.8 years 
versus 73.6 ± 5.1 years, P  0.05) as shown in Table 2.
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During the 2 months after the crossover, the total QOL 
scores and the daily living activity related QOL score were 
decreased in the group A that had switched from alendronate 
to alfacalcidol. No significant changes were observed in 
total, and “posture and figure” related QOL in the group B 
which switched from alfacalcidol to alendronate. However, 
total QOL and posture and figure related QOL increased 
significantly in the group B taking alendronate than com-
pared with group A, now taking alfacalcidol, during the 2 
month post-crossover period. This suggests that alendronate 
suppressed any decrease in QOL in group B, as shown in 
Figure 5.
According to pain intensity evaluated by VAS, group 
A had significantly increased upper back pain when taking 
alfacalcidol in the 2-month post-crossover period, while 
group B had no significant change in pain intensity with 
alendronate in any of the studied regions. No significant dif-
ference was observed in pain intensity changes between the 
two groups (Figure 6). These results suggest that switching 
to alfacalcidol from alendronate caused a decrease in QOL 
and increased pain.
Bone resorption measured by NTX was significantly 
increased in group A, which switched to alfacalcidol 
  during the 2 month post-crossover period, (20.3 ± 6.2 to 
28.4 ± 9.1 nM bone collagen-equivalent [BCE]/nM creatinine 
[Cr], while NTX was significantly decreased in the group B 
that switched to alendronate. This suggests that alendronate 
significantly suppresses the bone resorption more than alfa-
calcidol (P  0.01) as shown in Figure 7.
Discussion
The present study demonstrated that alendronate improved 
the QOL, especially pain related QOL, in postmenopausal 
osteoporotic Japanese women. The improvement in pain 
related QOL by alendronate was supported by the VAS pain 
intensity measurement; alendronate significantly reduced 
pain in the joints, and reduced any exacerbation of pain in the 
back, suggesting that pain reduction by alendronate contrib-
uted to the improvement of overall QOL in the patients.
The JOQOL questionnaire was created by the Japanese 
Society for Bone and Mineral Research to evaluate the QOL 
of Japanese osteoporotic patients based on the Osteoporosis 
Assessment Questionnaire in USA and the Questionnaire for 
Quality of Life by European Foundation for Osteoporosis 
(Qualeffo-42). It is a modification of the two questionnaires 
with additional questions that are suitable to the life style of 
Japanese women. According to the paper by Takahashi and 
colleagues, the JOQOL scores are correlated to the scores 
of Medical Outcomes Study Short Form 36 (SF-36) with 
coefficient r = 0.78 and reproducibility (r = 0.92).11
Although total QOL scores showed an increased trend 
with both alendronate and alfacalcidol in the first 4 months, 
Table 2 Patient baseline characteristics after crossover
Characteristic Group A (n = 18) alendronate Group B (n = 16) alfacalcidol P value
Age (year) 66.7 ± 9.1 73.6 ± 5.1 0.05
BMD Lumbar vertebrae (g/cm²) 0.639 ± 0.147 0.613 ± 0.164 ns
Urinary NTX (nmol BCE/nmol Cr) 49.0 ± 10.8 49.2 ± 23.6 ns
Vertebral fractures at baseline (yes/no) 3/9 2/8 ns
Family history of osteoporosis (yes/no) 2/11 5/5 ns
VAS (lower back) 5.0 ± 2.8 3.8 ± 1.4 ns
VAS (upper back) 3.3 ± 2.3 3.3 ± 2.4 ns
VAS (joints) 4.2 ± 2.1 2.5 ± 1.7 ns
JOQOL
Pain (20 points) 11.4 ± 4.7 13.8 ± 4.1 ns
Activity of daily living (64 points) 57.2 ± 8.9 55.0 ± 12.7 ns
Recreational and social activities (20 points) 11.6 ± 4.8 7.9 ± 5.0 ns
General health (12 points) 7.3 ± 3.9 7.5 ± 3.4 ns
Posture and figure (16 points) 11.5 ± 4.0 9.9 ± 2.8 ns
Falls and the psychological effects (20 points) 12.8 ± 4.3 11.3 ± 4.2 ns
Total QOL score (152 points) 72.8 ± 13.8 69.3 ± 11.6 ns
Abbreviations: NS, not significant; QOL, quality of life; VAS, visual analog scale; JOQOL, Japanese Osteoporosis Quality of Life Questionnaire; BMD, bone mineral density; 
NTX, urinary crosslinked N-terminal telopeptide of type I collagen; BCE, bone collagen-equivalent; Cr, creatinine.Clinical Interventions in Aging 2010:5 129
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the significant improvement of the total QOL was found 
only with alfacalcidol in the present study. However, 
among the QOL of six categories, alendronate significantly 
improved pain related QOL. In several previous studies, QOL 
improvement and pain reduction occurred with alendronate. 
Nevitt and colleagues demonstrated in a large scale 3-year 
randomized double blind study that alendronate reduced 
the number of days disability spent in bed, and the days of Clinical Interventions in Aging 2010:5 130
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limited activities caused by low back pain.4 Moreover, Dur-
sun and colleagues showed that alendronate and calcitonin 
reduced pain and improved the QOL equally after 6-months 
of treatment, when alendronate, calcitonin and calcium were 
compared for pain reduction, – when assessed by VAS and 
QOL improvement – as evaluated by the Nottingham Health 
Profile in an open-labeled study.7
The mechanism alendronate improves pain has not been 
clarified. The reduced incidence of bone fracture by alen-
dronate was suggested to reduce the pain.4 However in our 
study no new fractures were observed during the study period 
and the effect of alendronate on reducing pain appeared 
relatively quickly after the commencement of treatment. 
A marker for bone resorption, NTX, was decreased more 
with alendronate than with alfacalcidol. Although markers 
for bone metabolism and pain or QOL were not significantly 
associated in such a small scale study as ours, NTX reduc-
tion was positively associated with low back pain in 80 post 
menopausal women with osteoporosis reported by Iwamoto 
and colleagues.8 In patients with bone metastases or multiple 
myeloma, an intravenous treatment of bisphosphonates was 
shown to relieve skeletal pain within several weeks of the 
commencement of treatment.12–14 The timing for onset of 
the positive effects of the drug suggests that the effects of 
bisphosphonates on bone pain may not be explicitly related 
to an anti-osteoporotic effect, and likely to be associated with 
another mechanism of pain reduction.15
Within the local bone lesions, elevated inflammatory 
cytokines, prostaglandin and growth factors stimulate 
osteoclast activity and nociceptors to cause bone pain.16,17 
Since bisphosphonates were shown to reduce osteoclas-
togenic cytokines,18,19 this may explain the pain relieving 
effect. However, osteoclasts are known to degrade bone 
minerals by secreting protons through the vacuolar H+-
ATPase, creating acidic microenvironments.20–22 Nagae 
and colleagues23 proposed that osteoclasts plays an 
important role in producing bone pain by creating acidosis 
and through activating acid-sensing receptors of sensory 
neurons. In the study, bisphosphonates suppressed inflam-
matory hyperalgesia by inhibiting the effect of osteoclasts 
in the animal model.
There are limitations in the present study. The number of 
study patients is small and some baseline patient characteris-
tics were different between the groups; group A had a lower 
number of patients with a family history of osteoporosis and 
a slightly lower QOL in recreational and social activities 
when compared with the group B. This study was carried 
out as an open label study. There may be bias in the effect of 
the drugs. To confirm the results, a large double blind study 
must be conducted.
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Conclusion
Alendronate significantly suppressed pain when measured 
by a VAS, and by patient QOL measured by JOQOL, in 
postmenopausal osteoporotic patients. The efficacy of alen-
dronate is higher than that of alfacalcidol. The long term 
treatment of osteoporosis with alendronate not only prevents 
bone fracture, but also improves the patient’s QOL and 
reduces pain or prevents the exacerbation of pain.
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